Innoventric Cavalve™ Stent Graft First-in-Human (FIH) Study

Prospective, Single Arm, Multi-center, First-in-human (FIH) Study to Assess the Safety and Performance of the Innoventric Cavalve™ Stent Graft for the Treatment of Severe Tricuspid Regurgitation (TR)

A prospective, single-arm, multi-center first-in-human (FIH) study to evaluate the safety and performance of the Innoventric Cavalve™ Stent Graft System. Fifteen (15) patients in 4-5 investigational sites will be enrolled. All enrolled study patients will be assessed at baseline, during the procedure, at discharge, after 1 month, 3 months, 6 months, and 1 year following the index procedure.

Innoventric Cavalve™ Stent Graft First-in-Human (FIH) Study

Recruitment

Summary

Participation Requirements

Description

Tracking Information